For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for chimeric antigen receptor T-cell therapy (CAR-T), a recent game-changer for ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

WU-CART-007 is an investigational anti-CD7 CAR-T cell therapy for relapsed or refractory T-ALL/LBL, derived from healthy donor T cells to avoid malignant contamination. The phase 2 trial aims to ...

Remove this text and use the embed button to add an image. Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient. A2B694 therapy was well tolerated, showing no dose-limiting toxicities and ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...

-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months -- -- A more recent data cut will be ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the ...